Invest
   Home   |   Business News   |   Personal Finance   |   World News   |   U.S. News   |   Technology   |   Stock Alert   |   Stock Picks  |   Breaking News  |   Forex  |   Gold
Custom Search

Skechers USA Inc. (SKX) Has Jumped To A New High On Strong Q3 Earnings

Skechers USA Inc. (SKX) reported third quarter EPS of $0.59 after the close Thursday, up from $0.42 in the previous year. Analysts expected EPS of $0.43.

Danaher Corp. (DHR) Has Broken Out To A New High On Strong Q3 Earnings

Danaher Corp. (DHR) reported third quarter EPS of $1.00 Thursday morning, up from $0.87 in the prior year period. Analysts expected EPS of $0.95. The company expects to report fourth quarter adjusted EPS of $1.12 to $1.16 and full year adjusted EPS of $3.96 to $4.00. The consensus estimates are for EPS of $1.16 and $3.96.

Adobe Systems Inc. (ADBE) Has Jumped To A New High On Full Year Forecast

Adobe Systems Inc. (ADBE) reaffirmed its fourth quarter non-GAAP EPS forecast of $1.15 after the close Wednesday. The company also forecast full year 2018 non-GAAP EPS of $5.50. Street expectations are for EPS of $5.21.

Spectrum Pharmaceuticals Inc. (SPPI) Has Surged To A New High On Study Results

Spectrum Pharmaceuticals Inc. (SPPI) announced Tuesday that the interim data from its Phase 2 clinical study of poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer was presented in Yokohama, Japan.

IBM Corp. (IBM) Has Surged To Over A 5-Month High After Q3 Profit Beat

IBM Corp. (IBM) reported third quarter EPS of $3.30 after the bell Tuesday, compared to $3.29 in the prior year period. Street expectations were for EPS of $3.28.

Unitedhealth Group Inc. (UNH) Has Broken Out To A New High On Q3 Results

Unitedhealth Group Inc. (UNH) reported third quarter EPS of $2.66 Tuesday morning, up from $2.17 last year. The consensus estimate was for EPS of $2.56.

Exelixis Inc. (EXEL) Has Broken Out To A New High On FDA Priority Review

Exelixis Inc. (EXEL) announced Monday morning that its Phase 3 trial of cabozantinib in patients with advanced hepatocellular carcinoma met its primary endpoint.

AnaptysBio Inc. (ANAB) Has Soared To A New High On Phase 2 Study Results

AnaptysBio Inc. (ANAB) reported positive results from its Phase 2a trial of ANB020 Tuesday morning. An Eczema Area Severity Index score improvement of 50 percent relative to enrollment baseline was observed in 75 percent of patients after a single dose.
 
 
   DOW JONES
  
   NASDAQ
 
   S & P 500



 

  

 



 
 
 
   Latest News From CNN Money

Laptops could be banned from checked bags
Millions of Americans are left out of stock boom
Skechers stock soars as sneaker sales surge
Taser maker tumbles on news of SEC probe
GE's nightmare just got worse
 
 
   Latest News From The Wall Street Journal
Tesla Strikes Deal to Build Factory in China
 
  Home
  Business News
  Personal Finance
  World News
  U.S. News
  Technology

         

               
                 Copyright , Invest.